Strides JV gets USFDA nod for Albendazole tablets

New Delhi: Drug firm Strides Pharma Science recently said its joint venture (JV) firm has received approval from the US health regulator for Albendazole tablets, used in the treatment of certain infections caused by the tapeworm.

Strides Vivimed Pte Ltd, Singapore, a 50:50 joint venture with Vivimed Labs, has received approval from the United States Food & Drug Administration (US FDA) for Albendazole tablets in the strength of 200 mg, Strides Pharma Science said in a BSE filing.

This is the second generic approval by US FDA for Albendazole tablets, the company added.

Strides Pharma Science said the approved product is a generic version of Amneal Pharmaceuticals Inc's Albenza tablets.

Quoting IQVIA MAT data, Strides Pharma Science said the US market for Albendazole tablets USP 200 mg is approximately USD 100 million.

Strides Pharma Science Limited(Strides), incorporated in 1990, is a global pharmaceutical Company, headquartered in Bangalore, India. The Company is listed on the Bombay Stock Exchange and National Stock Exchange of India Limited.

Read Also: Strides Pharma board approves USD 15 million investment in Stelis Biopharma